

Date: November 05, 2024

To

BSE Limited,
Department of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001
BSE Scrip Code: 533014

Dear Sir/Madam,

Sub: Outcome of the Board meeting dated 05th November, 2024.

This is to inform that pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company, at its meeting held today, has inter alia, considered and approved the Un-Audited Standalone and Consolidated Financial Results of the Company along with the Limited Review Reports of the Auditors for the quarter & half year ended 30th September 2024. Copies of the aforesaid Un-audited Financial Results together with the Limited Review reports of the Auditors are enclosed herewith.

The Board has also considered and approved the sale of defoamer business (a portion of speciality chemicals division, which contributes only 0.37% of the overall revenue of the Company) for a sale consideration of Rs.2.50 Crores to Pennwhite India Pvt. Ltd, Chennai. Please note that even though the proposed sale does not come under the purview of the events/information which shall be disclosed under Regulation 30 in Para A of Part A of Schedule III of SEBI LODR Regulations 2015, we are making this information for a better corporate governance and transparency.

The above said unaudited financial results will be made available at the Company's website at www.sicagen.com

The meeting of the Board of Directors commenced at 03:30 p.m. (IST) & concluded at 04:33 p.m. (IST).

The above information may kindly be taken on record.

Thanking You,

Yours Sincerely,
For Sicagen India Limited



(Ankita Jain)
Company Secretary



Encl: As above

Sicagen India Ltd.

Registered & Corporate Office:

4th Floor, SPIC House, 88, Mount Road, Guindy, Chennai 600 032 INDIA

Tel: +91 44 4075 4075 | info@sicagen.com

CIN No.: L74900TN2004PLC053467 | www.sicagen.com